anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
The invention relates to penicillins I of formula &lt;FORM:1080247/C2/1&gt; and non-toxic salts thereof, where R is an aromatic or heteroaromatic residue which may be substituted and X is a divalent aliphatic hydrocarbon radical containing 1 to 4 carbon atoms which may bear a hydroxy substituent or be interrupted by an amide linkage.  The penicillins are prepared by hydrogenating or hydrolysing a penicillin II of general formula &lt;FORM:1080247/C2/2&gt; where X and R have the above meanings and Y is a nitrogen-containing group which is converted into a primary amino group, e.g. azido, benzyloxycarbonylamino or substituted benzyloxycarbonylamino group, enamine or o-hydroxyarylideneamino group.  Penicillins II are prepared by treating an aminopenicillin &lt;FORM:1080247/C2/3&gt; with an acylating agent or formula YXCOA, where X, R and Y have the above meanings and A is chlorine, azido, acyloxy, alkoxy-carbonyloxy, 1-imidazolyl or N,N1-disubstituted isoureido group derived from a carbodiimide. Alternatively, 6-aminopenicillanic acid may be reacted with a dipeptide acylating agent of formula &lt;FORM:1080247/C2/4&gt; wherein A, X, R and Y have the above meanings. Typical penicillins are 6-[a -(glycylamino) phenylacetamido] penicillanic acid and 6-[a -(b  - aminopropionamido) phenylacetamido] penicillanic acid.
&lt;P&gt;PROBLEM TO BE SOLVED: To disclose that MINOR and TR3 genes are insulin responsive genes differentially expressed as a function of insulin resistance and Type 2 diabetes in humans and a variety of well characterized animal models.  &lt;P&gt;SOLUTION: The present disclosure shows that MINOR and TR3 have a functional role in insulin resistance. Therefore, MINOR and TR3 are attractive and novel therapeutic targets for combating insulin resistance and/or disease states and conditions characterized by insulin resistance. Correlation of insulin resistance and disease states and conditions characterized by insulin resistance, (including Type II diabetes), with MINOR and TR3 gene expression are also disclosed. Methods of diagnosis, treatment and prevention are likewise disclosed for the treatment and/or prevention of insulin resistance and disease states or conditions characterized by insulin resistance.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
PROBLEM TO BE SOLVED: To obtain the subject new compound useful especially as an analgesic and free from side actions inherent to conventional analgesics. SOLUTION: The objective compound is expressed by the formula I (R&lt;1&gt; and R&lt;2&gt; are each H, a lower alkyl, etc.; R&lt;3&gt; is a lower alkyl or phenyl; R&lt;4&gt; is a hydroxy-lower alkyl, an oxo-lower alkyl, etc.), e.g. 2,6-dioxo-5-[methyl(4- methylphenyl)sulfoniol-1,2,3,6-tetrahydropyrimidin-4-olate. The compound can be produced e.g. by reacting a compound of the formula III with iodobenzene diacetate in the presence of an alkali such as sodium carbonate at 0 deg.C to room temperature for 1-10hr and reacting the resultant compound of the formula III with a thioether derivative of the formula R&lt;3&gt; -S-R&lt;4&gt; in a solvent such as methanol in the presence of an acid catalyst such as acetic acid at a temperature between room temperature and the refluxing temperature for 10 min to 30 hr.
The present invention relates to use of a sugar or a sugar alcohol eg. glycerol for protection of skin against harmful bacteria. The present invention is especially useful in formulating compositions which act as prebiotics by skin commensal bacteria like &lt;i&gt;S&lt;/i&gt;. &lt;i&gt;epidermidis&lt;/i&gt; to produce metabolites like lactic acid which by way of the present invention has been shown to inhibit growth of harmful bacteria like &lt;i&gt;E. Coli&lt;/i&gt; and &lt;i&gt;S&lt;/i&gt;. Aureus. The present invention is advantageous in that there is no need to use conventional antimicrobial actives which may destroy the skin microbiome.
A digestion helping and appetite stimulating pill belongs to the technical field of healthy foods. The digestion helping and appetite stimulating pill is formed by eleven raw medicines comprising Fructus Amomi, Radix Pseudostellariae, cinnamon, malt, chicken&#39;s gizzard membrane, dried orange peel, hawthorn fruit and other raw medicines, and is processed by using pharmaceutical apparatus to prepare a capsule, a tablet, a pill, a granule and an oral liquid for later use. The digestion helping and appetite stimulating pill has the efficacies of spleen invigorating, appetite stimulating, fat eliminating, stasis dissolving, qi moving, retention breaking, middle warmer regulating and food digesting. The digestion helping and appetite stimulating pill has good effects on impairment by overeating, apocleisis, poor appetite, dyspepsia, hyperlipidemia and other symptoms. The digestion helping and appetite stimulating pill is especially suitable for children to administrate. The digestion helping and appetite stimulating pill is a food, also has medicinal effects, and also has appetizing, food retention eliminating, appetite increasing, blood fat reducing and health maintaining effects. The digestion helping and appetite stimulating pill has the advantages of convenient administration, safety and no toxic side effects.
A method is disclosed. The method is generally useful for modifying a skin microbiome. The method comprises administering a topical composition to a subject&#39;s skin. A topical composition is also disclosed. The topical composition may be used for the method. The topical composition comprises a population of microorganisms, a component obtained from the population of microorganisms, or a combination thereof. The population of microorganisms is generally a  Corynebacterium  species. The  Corynebacterium  species comprises at least about 90%, optionally at least about 97%, sequence identity to a 16S rRNA sequence (SEQ ID NO: 1).
PURPOSE:To provide the titled composition containing alanine and ornithine as active component and having strong lifesaving effect, hepatic disorder mitigating effect and obnubilation mitigating effect. CONSTITUTION:The objective composition contains alanine and/or its salt and ornithine and/or its salt at a molar ratio of 1 to &gt;=0.001. It can be administered orally or parenterally, especially in the form of food preferably taken simultaneously to or just before or after the drinking of alcohol, e.g. a high-protein food such as smoked fish meat, oily food, high starch food, seasoning, alcoholic drink, soft drink, etc. The amount of the active component in the whole food is 0.01- 10%. The composition may contain other amino acids provided that the existence of the acids defeats the purpose of the invention.
An intelligent ventilator system and operating method thereof are provided. The system includes a ventilator and an input system. The ventilator includes an alarm system, a monitoring system, a communication unit, and a ventilator control system, where the ventilator is configured to apply respiratory treatment to a patient. The input system is configured to input the patient&#39;s parameters and treatment requirements to realize recordings of original data of a designed treatment plan. The ventilator control system calculates target data needed by the patient and design the treatment plan, and to control the ventilator. The communication unit is configured for data communication between the input system and the ventilator control system to realize transfer of data from the input system to the ventilator control system. The monitoring system is configured for real-time monitoring of patients, and the alarm system is configured to alarm in time according to the patient&#39;s urgency.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a means suppressing relapse and metastasis and further increasing the effect in radiotherapy of radiation resistant cancer except hypoxic state, by irradiating radiation in the presence of 1-(1-hydroxymethyl-2,3-dihydroxypropyl)oxymethyl-2-nitroimidazole.  &lt;P&gt;SOLUTION: In radiotherapy of cancer having radiation resistance, a radiation sensitizer of chemical formula 1 is used to sensitize and treat. The compound of chemical formula 1 of 10-400 mg is administered based on 1 kg body weight of animal or human and radiation is irradiated. The radiation resistant cancer is preferably lung adenocarcinoma. Fractionated irradiation therapy comprising administering 10-400 mg compound of formula 1 per 1 kg body weight to the animal or the human and then repeating 5-40 times irradiation of 1-10 Gy is preferable.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
A comprehensive medication management system is disclosed. The comprehensive medication management system offers a number of compliance related services that may be offered to patients in to improve medication therapy compliance. The system identifies compliance barriers facing individual patents and recommends services designed to overcome those barriers. The system further provides feedback to patients to document their progress. The system proactively identifies patients who may benefit from compliance services and blocks their transactions until the services are explained. The point of sale block may be expanded to other classes of patients so that the transactions of other classes of patients blocked and other messages delivered or some other customized interactions carried out. The medication management system may serve as a central repository of information about a patient&#39;s medication treatment program and the medication management system may provide quick and easy access to a patient&#39;s entire medication history to facilitate consultations between a pharmacist and the patient. The medication management system may generate lists of tasks for pharmacists to perform in order to deliver the compliance related services to individual patients.
PURPOSE:To prevent the lowering of pH due to oxidation as well as to enhance safety by using a maltitol hydroxy aliphatic ether having a specified structure, monostearic acid glycerol and water. CONSTITUTION:A compsn. consisting of 1pt. wt. maltitol hydroxy aliphatic ether represented by the formula [where A is a residue obtd. by removing 1-3 (n) hydroxyl groups from maltitol, each of R&lt;1&gt; and R&lt;2&gt; is H, 1-20C alkyl or branched alkyl and (n) is an integer of 1-3], 0.5-5 pts.wt. monostearic acid glycerol and 3-90 pts.wt. water is blended with 0.5-5 pts.wt. higher alcohols to obtain the objective gelatinous compsn. and this compsn. is further blended with 1-30 pts.wt. oil to obtain the objective emulsified compsn. When each of the gelatinous and emulsified compsns. is added to an endermic liniment, the amt. of the maltitol hydroxy aliphatic ether is regulated to 0.01-30.0wt.%, preferably 0.1-10.0wt.% of the amt. of the liniment.
NEW MATERIAL:The oxazole derivative of formula I (R&lt;1&gt; is H or lower alkyl; R&lt;2&gt; is H, halogen, CF3, or lower alkylthio; R&lt;3&gt; is H or lower alkyl; n is 1 or 2) or its salt. EXAMPLE:4-(4-Chlorophenyl)-2-methyloxazole-5-propionic acid. USE:Remedy for diabetes. It has low toxicity and blood sugar level depressing activity, and is effective to improve the resistance to sugar and to promote the sensitivity to insulin. Dose; preferably 2-20mg/kg daily for adult by oral administration in 2-3 divided doses. PROCESS:The compound of formula I can be prepared e.g. by reacting the compound of formula II (X is halogen) with the compound of formula III in the absence of solvent, if necessary in the presence of a base such as Na2CO3 under heating at 80-160 deg.C. When the resultant compound is an ester, it can be converted to carboxylic acid by hydrolysis, and when it is a carboxylic acid, it can be esterified to obtain an ester compound.
A large number of domestic and foreign research results and abundant report data and abundant reports data show clearly that periodontal diseases are closely related to cardiovascular and cerebrovascular diseases. People notices that the chief culprit of the cardiovascular and cerebrovascular diseases is in-oral-cavity periodontal pathogen entering into the blood circulation, so that the people puts forward a preventive measure using a strong fungicide to kill the in-oral-cavity periodontal pathogen; but normal bacterium colonies are also killed by the measure, the measure is  undesirable. British (Daily Mail) website reports that heart disease and stroke probability can be reduced by frequent tooth brushing. Poor oral hygiene and gum bleeding can lead to as many as 700 kinds of bacteria into the blood, so that &#39;cleaner oral cavity, healthier heart&#39; is put forward. The applicant thinks frequent use of a paper patch is more effective than tooth brushing for that reason that the paper patch can absorb pathogen, and can protect the oral mucosa barrier to prevent bacteria invasion of the blood circulation. Daily tooth brushing is the daily life habit of the people, by daily use of the paper patch (for middle aged and elderly people), the oral cavity can be cleaner, the heart can be healthier, and the brain can be more normal. The paper patch is a life prolonging health-care product for the middle aged and elderly people.
To provide a health state management device that can appropriately manage a state of a user&#39;s health.SOLUTION: A health state management device 100 comprises: a management information storage unit; a threshold calculation unit 112; a threshold transmission unit 113; a measurement information acquisition unit 111; a health state determination unit 114; and a health state notification unit 115. The management information storage unit stores identification information for identifying a user in association with user management information. The threshold calculation unit 112 calculates a threshold used for determining a user&#39;s body temperature on the basis of the management information. The threshold transmission unit 113 transmits the threshold to a biometric authentication device that identifies the user and measures the user&#39;s body temperature. The measurement information acquisition unit 111 acquires, from the biometric authentication device, the user&#39;s measured body temperature and a result of body temperature determination for determining the measured body temperature based on the threshold. The health state determination unit 114 determines a state of the user&#39;s health on the basis of the management information, the measured body temperature, and the body temperature determination result.SELECTED DRAWING: Figure 5
FIELD: medicine. ^ SUBSTANCE: invention relates to field of medicine, namely to neurosurgery, traumatology and surgery and is intended for surgical treatment of decubital wounds in case of separation of adjacent tissues in patients with consequences of spinal cord trauma. Cavity of decubital wound is densely tamponed with turunda preliminarily soaked in solution of methylene blue and 3% hydrogen peroxide with ratio of ingredients in solution 9:1. Entrance gate of decubital wound is tightly sewn with interrupted sutures. On skin, transversely to gluteal fold projection, marked is cut of ellipsoid shape sufficient for excision of bedsore capsule, with which sewn entrance gate of decubital wound are located inside excised skin section. Skin cut is performed. Pathologic focus is ablated in one block, guided by size of tamponed cavity and stained tissues. &#34;Blind&#34; draining of operation wound with further plasty of skin-muscular flap is performed. Antibacterial therapy is carried out for 5 days. Drainage is removed after 3 days. ^ EFFECT: method makes it possible to achieve complete and quality excision of decubital wound, reduce probability of recurrent surgery due to application of methylene blue and 3% hydrogen peroxide, extending narrow ways and slit recesses for complete staining and converting surgery from type of &#34;purulent&#34; into type of &#34;clean&#34; ones. ^ 1 ex
PURPOSE:To obtain the titled vaccine on an industrial scale, by cultivating Bordetella pertussis with aeration and agitation under specific conditions, increasing an infection protective antigen HA fraction together with the multiplication of the Bordetella pertussis, and detoxicating the above-mentioned HA fraction in the presence of an amino acid. CONSTITUTION:Bordetella pertussis is inoculated into a liquid culture medium containing cyclodextrin or a derivative thereof. In the process, the cultivation temperature is kept at 20-37 deg.C, and the amount of dissolved oxygen in the culture medium is kept at 0.7-6ppm. Furthermore, the culture medium is preferably defoamed under conditions of 6&lt;pH&lt;9 for the cultivation with aeration and agitation. The aimed infection protective antigen HA fraction is then collected in the bacterial growth stage in the ogarithmic growth phase or stationary phase and then detoxicated in the presence of an amino acid, e.g. glycine or methionine. The resultant detoxicated HA fraction can be used to produce purified pertussis vaccine, precipitated purified pertussis vaccine, precipitated purified pertussis and diphtheris and tetanus mixed vaccine, etc. economically in large amounts.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method of reducing pre-existing humoral immunity to immunogenic viral treatment agent, and its composition.  &lt;P&gt;SOLUTION: A method of reducing pre-existing humoral immunity to a viral immunogenic therapeutic agent such as adenovirus, using immunoapheresis is disclosed. Antibodies specific for the viral immunogenic therapeutic agent are selectively removed from the blood of an individual prior to administration of the viral immunogenic therapeutic agent on an extracorporeal reaction with an immunosorbent which specifically binds the antibodies. After the antibodies are selectively removed from the blood, the blood is reinfused into the patient and then the viral immunogenic therapeutic agent is administered. The invention also provides a kit and composition for selectively removing anti-viral antibodies.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
A composition (c1) in the form of an oil-in-water emulsion, with an oily phase dispersed in an aqueous phase, comprises an emulsifying system containing at least one nonionic surfactant with a melting point of less than 45[deg]C and an HLB ranging of 10 - 15, and at least one anionic surfactant; and at least one hydrophilic UV-screening agent. A composition (c1) in the form of an oil-in-water emulsion, with an oily phase dispersed in an aqueous phase, comprises an emulsifying system containing at least one nonionic surfactant with a melting point of less than 45[deg]C and an HLB ranging of 10 - 15, and at least one anionic surfactant; and at least one hydrophilic UV-screening agent. The surfactant with a polar portion contains at least 5 oxyethylene groups and an apolar portion contains at least one branched or unsaturated 14-22C alkyl chain. The oily phase comprises oily constituents that includes (wt.%): at least one hydrocarbon-based oil (h1) with a molecular weight of &gt;= 400 (at least 25) and triglyceride-based oils (less than 15). The weight ratio of the amount of oily constituents of the oily phase to the amount of emulsifying system is 0.8 - 3.5. Independent claims are included for the following: (1) an article obtained by impregnating a water-insoluble substrate with (c1); and (2) a process for preparing the (c1) involving preparing the oily phase (A) comprising the oil(s) and other fatty substances, and the emulsifying system with stirring at 20 - 45[deg]C until a homogeneous phase is obtained, introducing into phase (A) 0.1 - 3 wt.% of water (phase B) and mixing until a homogeneous phase (C) is obtained, adding to phase (C) 55 - 75 wt.% water (phase D) to obtain after mixing a homogeneous phase E, and optionally adding any further constituents of the aqueous phase (phase F). ACTIVITY : Dermatogical. MECHANISM OF ACTION : None given.
This invention relates to an application of distiller&#39;s grain protein used for preparing pharmaceutical for increasing human sports ability, enhancing body composition and fatigue resistance, and reducing inflammatory reaction while performing sports training. The distiller&#39;s grain protein is sake protein. The sports ability includes muscle strength and muscle endurance. Enhancing body composition includes reducing fat. Fatigue resistance includes reducing blood lactate, blood ammonia, and creatinine kinase, and increasing glycogen. Reducing inflammatory reaction includes reducing aspartate aminotransferase (AST), lactate dehydrogenase (LDH), creatinine, and uric acid (UA) increased due to sports. An effective amount of distiller&#39;s grain protein is 12g-31g daily.
An implant-supported denture placement and alignment system may include a denture apparatus. The denture apparatus may have a denture base and a denture base positioning system. The denture base may be connectable to implants. Moreover, the denture base positioning system may position the denture base in substantially the same position as a surgical guide used to place the implants. In this manner, the denture apparatus may be positioned so that it is mountable to the implants placed according to the surgical guide following their placement in a patient&#39;s mouth. In this manner, variations in the placement of the implants arising during the process of installing the implants may be compensated by transferring the actual implant positioning to the denture apparatus when it is positioned by the denture base positioning system.
CD30 is a receptor expressed on cells of Hodgkin&#39;s disease and certain leukemias. The extracellular portion of CD30 is cleaved, releasing a form known as sCD30. The invention relates in part to the discovery that a residual, extracellular “stalk” of CD30 remains after cleavage of sCD30. The stalk provides an advantageous and previously unrecognized target for immunotoxins. The invention provides antibodies that bind to the CD30 stalk or to epitopes destroyed upon the cleavage of CD30 which results in the stalk. The invention further provides new anti-CD30 antibodies that form effective immunotoxins and are particularly suitable for making disulfide stabilized Fv (“dsFv”)-immunoconjugates. The dsFv immunoconjugates can be used as reagents to label CD30-expressing cancer cells or to inhibit the growth of CD30-expressing cancer cells. Moreover, the invention provides anti-CD30 antibodies that activate complement-dependent cytotoxicity.
A commercially-suitable tricholine nasal formulation for administration to a human as a nasal spray is disclosed. The tricholine nasal formulation includes an aqueous solution of tricholine citrate, a volatile oil and, optionally a buffer system. The disclosed tricholine nasal formulation possesses an acceptable odor and a reasonable shelf-life. The tricholine nasal formulation may be used to treat the symptoms associated with stress, anxiety, depression, malaise, or &#34;burn out&#34; syndrome. Optionally, a moisturizer is included to the composition to alleviate any dryness, if such a dryness should result from administration of the formulation to a user. A preservative may be included in the composition to produce a longer shelf- life.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an expression system which provides heterologous proteins expressed by a non-native host organism but which have native-protein-like biological activity and/or structure.  &lt;P&gt;SOLUTION: An expression system provides heterologous proteins expressed by a non-native host organism but which have native-protein-like biological activity and/or structure. Disclosed are vectors, expression hosts and methods for expressing the heterologous proteins. The expression system involves co-expression of protein factor(s) which is/are capable of catalyzing disulphide bond formation and desired heterologous protein(s). The expression system is presented using yeast cells as the preferred host, protein disulphide isomerase (PDI) and thioredoxin (TRX) as the preferred examples of the protein factors and HCV-E2&lt;SB&gt;715&lt;/SB&gt;envelope glycoprotein and human FIGF as the preferred examples of the heterologous proteins.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT